Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS002 for Cancer Bone Metastasis Pain (Ib/IIa)
CTR20221914Phase 2Completed
- Sponsor
- Dashi Pharmaceuticals
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DS002 in cancer pain, sponsored by Dashi Pharmaceuticals. Started Aug 2022; status: completed.
02
Drugs
DS002
03
Conditions
cancer pain
Beyond the preview
Go deeper on CTR20221914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221914.